Wayne State U and MITRI Partner to Move Neuro Rx Candidates to Clinical Trials | GenomeWeb

The Michigan Technology and Research Institute and Wayne State University have partnered to commercialize three small molecule compounds developed by WSU researchers with the potential to treat an array of neurological conditions, the university said this week.

As part of their deal, MITRI and WSU have inked a letter of intent to form a company to ready for clinical trials the most advanced of the compounds, a small molecule triple-uptake inhibitor for treating depression, at which point they hope to attract a pharma partner for further development.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.